Literature DB >> 24912856

Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.

Jonel Trebicka1, Cyrus Wix, Matthias von Heydebrand, Kanishka Hittatiya, Thomas Reiberger, Sabine Klein, Robert Schierwagen, Glen Kristiansen, Markus Peck-Radosavljevic, Hans-Peter Fischer, Søren Møller, Flemming Bendtsen, Aleksander Krag, Tilman Sauerbruch.   

Abstract

BACKGROUND & AIMS: Patients with cirrhosis display hypocontractility of splanchnic vessels because of dysregulation of vasoactive proteins, such as decreased effect of RhoA/ROCK and increased activity of β-Arrestin-2 and eNOS. However, it is unknown whether the dysregulation of vasoactive proteins is displayed in other vessels. We investigated whether expression of vasoactive proteins can be evaluated in gastric mucosa vessels.
METHODS: Biopsies from the gastric mucosa of 111 patients with cirrhosis were collected at three different centres and from 13 controls. Forty-nine patients had received TIPS. Portal pressure gradient was measured in 49 patients with TIPS and in 16 patients without TIPS. Biopsies from the antrum were conserved in formaldehyde for immunohistochemistry or shock-frozen for PCR and Western blot.
RESULTS: The mucosal transcription of vascular markers (αSMA, CD31) was higher in cirrhotic patients than controls, which was confirmed by immunohistochemistry. On average, relative mucosal levels of RhoA and ROCK were lower, while β-Arrestin-2 levels were higher in cirrhotic patients compared to controls. Transcriptional levels of eNOS increased with presence of ascites and grade of oesophageal varices. Patients with TIPS showed less pronounced markers of vascular dysfunction in gastric mucosa.
CONCLUSION: This is the first evidence that the expression of vasoactive proteins in mucosa from the gastric antrum of patients with cirrhosis reflects their vascular dysfunction and possibly changes after therapeutic interventions.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; portal hypertension; transjugular intrahepatic portosystemic shunt; vascular dysfunction; vasoactive pathways

Mesh:

Substances:

Year:  2014        PMID: 24912856     DOI: 10.1111/liv.12613

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.

Authors:  Tom Luedde; Jonel Trebicka; Frank Erhard Uschner; Florian Schueller; Ivelina Nikolova; Sabine Klein; Robert Schierwagen; Fernando Magdaleno; Stefanie Gröschl; Sven Loosen; Thomas Ritz; Christoph Roderburg; Michael Vucur; Glen Kristiansen; Twan Lammers
Journal:  Oncotarget       Date:  2018-11-16

2.  Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.

Authors:  Sabine Klein; Franziska Frohn; Fernando Magdaleno; Catharina Reker-Smit; Robert Schierwagen; Irela Schierwagen; Frank Erhard Uschner; Fransien van Dijk; Dieter O Fürst; Sonja Djudjaj; Peter Boor; Klaas Poelstra; Leonie Beljaars; Jonel Trebicka
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

3.  Portal hypertensive gastropathy is associated with iron deficiency anemia.

Authors:  Benedikt Simbrunner; Andrea Beer; Katharina Wöran; Fabian Schmitz; Christian Primas; Marlene Wewalka; Matthias Pinter; Werner Dolak; Bernhard Scheiner; Andreas Puespoek; Michael Trauner; Georg Oberhuber; Mattias Mandorfer; Thomas Reiberger
Journal:  Wien Klin Wochenschr       Date:  2020-01-07       Impact factor: 1.704

4.  β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study.

Authors:  Sameh A Lashen; Mohammed M Shamseya; Marwa A Madkour; Radwa M Abdel Salam; Sanaa S Mostafa
Journal:  World J Hepatol       Date:  2022-02-27

5.  Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.

Authors:  Frank E Uschner; Ganesh Ranabhat; Steve S Choi; Michaela Granzow; Sabine Klein; Robert Schierwagen; Esther Raskopf; Sebastian Gautsch; Peter F M van der Ven; Dieter O Fürst; Christian P Strassburg; Tilman Sauerbruch; Anna Mae Diehl; Jonel Trebicka
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

6.  β-Arrestin2 is increased in liver fibrosis in humans and rodents.

Authors:  Robert Schierwagen; Peter Dietrich; Sabine Klein; Frank Erhard Uschner; Cristina Ortiz; Olaf Tyc; Sandra Torres; Claus Hellerbrand; Tilman Sauerbruch; Jonel Trebicka
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-03       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.